VSTM · Company research
Verastem, Inc. (VSTM): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
24records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| (VSTM) Risk Channels and Responsive Allocation - Stock Traders Daily | (VSTM) Risk Channels and Responsive Allocation Stock Traders Daily | View source ↗ | Stock Traders Daily | Oct 17, 2026 | neutral | 0 | 0.6 |
| Verastem (VSTM) Shares Jumped On Trial Data And Funding, Is The Stock Still Cheap? - Yahoo Finance | Verastem (VSTM) Shares Jumped On Trial Data And Funding, Is The Stock Still Cheap? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 16, 2026 | neutral | 0 | 0.6 |
| VSTM Stock Clocks Best Day In 11 Months After Positive Cancer Drug Trial Update And Multiple Price-Target Hikes - Stocktwits | VSTM Stock Clocks Best Day In 11 Months After Positive Cancer Drug Trial Update And Multiple Price-Target Hikes Stocktwits | View source ↗ | Stocktwits | Oct 15, 2026 | neutral | 0 | 0.6 |
| Verastem Oncology Announces CEO Transition to Michael Bailey - The Globe and Mail | Verastem Oncology Announces CEO Transition to Michael Bailey The Globe and Mail | View source ↗ | The Globe and Mail | Oct 15, 2026 | neutral | 0 | 0.6 |
| Verastem, Inc. (VSTM) Discusses New Clinical Data for VS-7375 KRAS G12D Inhibitor in Pancreatic, Lung, and Colorectal Cancers - Slideshow (NASDAQ:VSTM) 2026-10-14 - Seeking Alpha | Verastem, Inc. (VSTM) Discusses New Clinical Data for VS-7375 KRAS G12D Inhibitor in Pancreatic, Lung, and Colorectal Cancers - Slideshow (NASDAQ:VSTM) 2026-10-14 Seeking Alpha | View source ↗ | Seeking Alpha | Oct 14, 2026 | neutral | 0 | 0.6 |
| VSTM 424B Filings - Verastem, Inc. SEC 424B - Stock Titan | VSTM 424B Filings - Verastem, Inc. SEC 424B Stock Titan | View source ↗ | Stock Titan | Oct 14, 2026 | neutral | 0 | 0.6 |
| VSTM Stock Draws Bullish Targets As Ovarian Cancer Data Impress - Timothy Sykes | VSTM Stock Draws Bullish Targets As Ovarian Cancer Data Impress Timothy Sykes | View source ↗ | Timothy Sykes | Oct 14, 2026 | neutral | 0 | 0.6 |
| VSTM Stock Draws Bullish Targets As Cancer Data Strengthens - StocksToTrade | VSTM Stock Draws Bullish Targets As Cancer Data Strengthens StocksToTrade | View source ↗ | StocksToTrade | Oct 14, 2026 | neutral | 0 | 0.6 |
| VSTM Stock Draws Bulls As Oncology Data And Targets Rise - StocksToTrade | VSTM Stock Draws Bulls As Oncology Data And Targets Rise StocksToTrade | View source ↗ | StocksToTrade | Oct 14, 2026 | neutral | 0 | 0.6 |
| VSTM Stock Draws Bullish Targets As Cancer Data Impress - Timothy Sykes | VSTM Stock Draws Bullish Targets As Cancer Data Impress Timothy Sykes | View source ↗ | Timothy Sykes | Oct 14, 2026 | neutral | 0 | 0.6 |
| Why Did VSTM Stock Surge 14% In Pre-Market Today? - Stocktwits | Why Did VSTM Stock Surge 14% In Pre-Market Today? Stocktwits | View source ↗ | Stocktwits | Oct 14, 2026 | neutral | 0 | 0.6 |
| Verastem Oncology (VSTM) Shares Surge 20% Premarket on CEO Change and $250M Stock Offering - GuruFocus | Verastem Oncology (VSTM) Shares Surge 20% Premarket on CEO Change and $250M Stock Offering GuruFocus | View source ↗ | GuruFocus | Oct 14, 2026 | neutral | 0 | 0.6 |
| Verastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants - Stock Titan | Verastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants Stock Titan | View source ↗ | Stock Titan | Oct 14, 2026 | neutral | 0 | 0.6 |
| Two of 22 pancreatic cancer patients had complete responses to an experimental drug; one is unconfirmed. - Stock Titan | Two of 22 pancreatic cancer patients had complete responses to an experimental drug; one is unconfirmed. Stock Titan | View source ↗ | Stock Titan | Oct 14, 2026 | neutral | 0 | 0.6 |
| Verastem, Inc. (VSTM) stock price, news, quote and history - Yahoo Finance UK | Verastem, Inc. (VSTM) stock price, news, quote and history Yahoo Finance UK | View source ↗ | Yahoo Finance UK | Oct 13, 2026 | neutral | 0 | 0.6 |
| Verastem, Inc. (VSTM) Stock Price, News, Quote & History - Yahoo! Finance Canada | Verastem, Inc. (VSTM) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 12, 2026 | neutral | 0 | 0.6 |
| Does Verastem (VSTM) Have the Potential to Rally 79% as Wall Street Analysts Expect? | Verastem (VSTM) closed at $8.38 with a mean analyst price target of $15, suggesting 79% upside potential. The stock has gained 14.5% over the past four weeks. Analysts have revised earnings estimates higher, and VSTM holds a Zacks Rank #2 (Buy) rating. However, the article cautions that price targets should not be the sole basis for investment decisions, as they are often overly optimistic. | View source ↗ | Zacks Investment Research | Oct 12, 2026 | bullish | 1 | 1 |
| Verastem Stock Price Forecast. Should You Buy VSTM? - StockInvest.us | Verastem Stock Price Forecast. Should You Buy VSTM? StockInvest.us | View source ↗ | StockInvest.us | Oct 9, 2026 | neutral | 0 | 0.6 |
| Verastem (NasdaqCM:VSTM) Stock Forecast & Analyst Predictions - Simply Wall Street | Verastem (NasdaqCM:VSTM) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Oct 8, 2026 | neutral | 0 | 0.6 |
| Strength Seen in Genmab (GMAB): Can Its 10.7% Jump Turn into More Strength? | Genmab shares rallied 10.7% following positive phase III trial data for epcoritamab in combination with R-CHOP for newly diagnosed diffuse large B-cell lymphoma. The stock's consensus EPS estimate was revised 8.7% higher over the past 30 days, though earnings are expected to decline 43.1% year-over-year while revenues grow 15.7%. The stock carries a Zacks Rank #3 (Hold) rating. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 0.333 | 1 |
| Strength Seen in Genmab (GMAB): Can Its 10.7% Jump Turn into More Strength? | Genmab shares rallied 10.7% following positive phase III trial data for epcoritamab in combination with R-CHOP for newly diagnosed diffuse large B-cell lymphoma. The stock's consensus EPS estimate was revised 8.7% higher over the past 30 days, though earnings are expected to decline 43.1% year-over-year while revenues grow 15.7%. The stock carries a Zacks Rank #3 (Hold) rating. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 0.333 | 1 |
| Verastem (VSTM) Stock Sees Fair Value Moves Lower As Analysts Cut Revenue Views - Yahoo Finance | Verastem (VSTM) Stock Sees Fair Value Moves Lower As Analysts Cut Revenue Views Yahoo Finance | View source ↗ | Yahoo Finance | Aug 25, 2026 | neutral | 0 | 0.6 |
| $VSTM stock is up 8% today. Here's what we see in our data. - Quiver Quantitative | $VSTM stock is up 8% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 17, 2026 | neutral | 0 | 0.6 |
| VSTM Forecast — Price Target — Prediction for 2027 - TradingView | VSTM Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 26, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.